The Bott Cancer Center at Holy Redeemer Hospital is proud to provide advanced cancer care to our patients and community by offering a variety of cancer clinical trials. Cancer clinical trials are research studies in which people and health care professionals work together to improve cancer care. They provide answers to scientific questions and help to find better ways to prevent, diagnose, or treat cancer. People who choose to take part in cancer clinical trials have an opportunity to contribute to the advancement of cancer care, while receiving the latest treatment options from clinical experts.
Holy Redeemer’s Institutional Review Board (IRB) supports the cancer clinical trials program by reviewing each clinical trial to ensure the study is conducted fairly and the rights and welfare of volunteer participants are protected. Holy Redeemer’s IRB is made up of doctors, researchers, nurses, pharmacists, local leaders, and other members of the community who are committed to our goal to provide the highest quality of care to our community.
As a member of the Sidney Kimmel Cancer Network at Jefferson,
Holy Redeemer is able to provide access to trials sponsored by the National Cancer Institute. In addition, through membership with the Sidney Kimmel Cancer Center, we are able to provide access to select National Institute of Health supported clinical trials that have been developed by researchers at Jefferson.
Clinical trials are completely voluntary; participation is a personal decision that should be made by each individual in conjunction with their physician and family. Please speak with your doctor to find out if a clinical trial is right for you or your loved one.
If you are interested in learning more about clinical trials at the Bott Cancer Center, please speak with your doctor or call our Clinical Trials Office at 215-938-3551.
Collapse all | Expand all
ECOG 2108: A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in patients with Metastatic Breast Cancer.
This study compares a different treatment approach for breast cancer, which has spread beyond the breast to other parts of the body with the standard or usual treatment.
NSABP B51/RTOG 1304: A Randomized Phase III Clinical Trial evaluating Post-Mastectomy Chest Wall, Regional Node XRT and Post-Lumpectomy Regional Nodal XRT in patients with Positive Axillary Nodes before Neoadjuvant Chemotherapy who convert to Pathologically Negative Axillary Nodes after Neoadjuvant Chemotherapy.
This study compares if the addition of chest wall + regional nodal XRT after mastectomy or the regional nodal XRT, in addition to breast XRT after breast conserving surgery, will significantly reduce the rate of events for invasive breast cancer recurrence-free intervals in patients who initially have confirmed positive biopsy axillary nodes, but convert to negative axillary nodes following neoadjuvant chemotherapy.
A011202: A Randomized Phase III Trial comparing Axillary Lymph Node Dissection to Axillary Radiation in breast cancer patients (cT1-3 N1) who have Positive Sentinel Lymph Node Disease after Neoadjuvant Chemotherapy.
This study compares whether removing some of the lymph nodes from the arm pit, but not removing them all, followed with radiation therapy (experimental) will be as good as having the majority of the lymph nodes from the arm pit removed during breast surgery followed with radiation (standard of care).
S1202: A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor (AI)—associated Musculoskeletal Symptoms in women with early stage breast cancer.
This study compares the effects, good and/or bad, of the medication duloxetine compared to placebo (contains no active ingredient) on your joint pain that is associated with taking aromatase inhibitors. Duloxetine is a drug usually prescribed to treat depression or anxiety, pain caused by nerve damage or fibromyalgia (a painful muscle/bone/nerve disorder) and a muscle and bone pain from a type of arthritis. Researchers on this study want to see if the pain relieving effects of the drug work for your type of pain.
CALGB 30610: A Phase III Comparison of Thoracic Radiotherapy Regimens in patients with Limited Small Cell Lung Cancer also receiving Cisplatin and Etoposide.
This study looks at 2 different ways to give radiation therapy for patients with limited stage small cell lung cancer that has not been detected outside the chest.
Lung Cancer Screening Program Using Low Dose CT Scan with Prospective Patient Outcome Data Collection: The National Cancer Institute (NCI) conducted a large national lung screening trial (NLST), which showed a benefit in detecting lung cancer earlier in heavy smokers using LDCT. Essentially, it comes down to how long and how much you have smoked in your lifetime. At this time, most insurance does not cover this scan and there is a cost ($289); however, this test can be very valuable in detecting early stage lung cancer, when it is most treatable.
For more information, call 215-938-LUNG or click here.
For more information on Clinical Trials, please visit the following websites:
National Cancer Institute